21/04/2017 18:39:45

MPI increases its share capital with nominal DKK 6,190 as a result of exercise of 123,800 warrants

Hoersholm; April 21st 2017 - Medical Prognosis Institute A/S (MPI) announced today that, as a consequence of an exercise of warrants the share capital has been increased by nominal DKK 6,190 and the number of shares has been increased with 123,800.

The increase is affected without any pre-emption rights for the existing shareholders of the company or others. The shares are subscribed in cash at a price of DKK 0.52 per share of nominally DKK 0.05.

Proceeds to the company are DKK 64,376.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2016. MPI's current share capital amounts to DKK 1,174,452 and will after the capital increase be DKK 1,180,642. The capital increase is expected to be finalized shortly.

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)

MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given   anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP(TM) is a Big Data tool based on messenger RNA.

The DRP(TM) platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.

About MPI

Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,100 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.

For further information, please contact:

CEO, Peter Buhl Jensen, Adjunct Professor, MD, PhD                              Ulla Hald Buhl, IR & Communication

E-mail: pbj@medical-prognosis.com                                                          E-mail: uhb@medical-prognosis.com

Telephone: +45 21 60 89 22                                                                       Telephone +45 21 70 10 49

This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 21

st

2017.

Certified Advisor:

Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sweden

MPI - Increases its share capital due to warrant exercise April 2017


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Medical Prognosis Institute via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
14 Oct
PNDORA
Har efterhånden læst mange indlæg om Pandora her på Euroinvestor. De fleste indlæg er enten beregne..
21
13 Oct
PNDORA
Det ligger klart for enhver at med vaekst rater over 10 procent om aaret, som vedholdende vil blive ..
16
16 Oct
VWS
Kommentarer, hvorfor anvender du nu en periode på 13 måneder, når du ser tilbage for at sammenligne ..
11
17 Oct
I:DAX
Suspenderer sikkert al sikkert al handel i Frankfurt  hvis den falder -0,3% Hvad hedder det så hvis..
10
14 Oct
VWS
Earlier this year, China's National Energy Administration announced it would spend $363 billion by 2..
10
13 Oct
VWS
Kommentarer, du svarede ikke på mit indlæg til dig sidst. Måske du ikke så det? Jeg stillede spørgsm..
10
16 Oct
OMXC25
Jeg har fuldstændig mistet enhver form for respekt for EU.   EU er i den grad blevet til en taberfor..
9
16 Oct
VWS
Hej Kommentarer. Dejligt du lige kan påminde os om, hvordan kursudviklingen har været, det har været..
9
15 Oct
VWS
Skotland's nationalist party har i denne uge annonceret at de arbejder frem imod at lave et nyt stat..
9
17 Oct
GEN
Hvis jeg var lige så sikker i mine forudsigelser på aktier, som mine forudsigelse på at du inden for..
8

Admiral Group PLC : Director/PDMR Shareholding

29/09/2017 14:53:59
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM 1 Details of the person discharging managerial responsibilities (PDMR)/person closely associated with them (PCA) a) Name Annette Court 2 ..

Man Group PLC : Form 8.3 - [Clinigen Group plc]

29/09/2017 12:19:01
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Man Group Plc (b) Owner or controller..

Invesco Ltd. : Form 8 (DD) - IP Group Plc

29/09/2017 10:46:56
                                                            FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
NAVIENT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Navient Corporation - (NAVI)
2
Smithfield Foods’ Helping Hungry Homes® and Kroger Donate More Than 39,000 Pounds of Protein to God’s Pantry Food Bank
3
Plan a Cruise Month, Week Three: Cruise Lines International Association (CLIA) Shines Spotlight on Australasia Cruise Travel
4
Saniona AB: Saniona's Partner Cadent Therapeutics Receives Milestone from Novartis
5
CGG: Availability of a securities note supplement to the prospectus approved by the AMF under visa no.17-551 on October 13th, 2017

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 October 2017 08:39:48
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171017.1 - EUROWEB6 - 2017-10-18 09:39:48 - 2017-10-18 08:39:48 - 1000 - Website: OKAY